Literature DB >> 24052312

Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought.

Sylvie Bonvalot1, Nils Ternès, Marco Fiore, Georgina Bitsakou, Chiara Colombo, Charles Honoré, Andrea Marrari, Axel Le Cesne, Federica Perrone, Ariane Dunant, Alessandro Gronchi.   

Abstract

PURPOSE: The relevance of the initial observational approach for desmoid tumors (DTs) remains unclear. We investigated a new conservative management treatment for primary abdominal wall DTs.
METHODS: Data were collected from 147 patients between 1993 and 2012. The initial therapeutic approaches were categorized as front-line surgery [surgery group (SG), n = 41, 28 %] and initial observation or medical treatment [nonsurgery group (NSG), n = 106, 72 %]. The cumulative incidence of the last strategy modification was estimated using competing risk methods with variable censoring times.
RESULTS: Of the 147 patients, 143 were female (97 %). In the SG, 27 patients (66 %) required full-thickness abdominal wall mesh repair. In the NSG, 102 patients (96 %) underwent initial observation and four received medical treatment. In the NSG, the 1- and 3-year incidences of changing to medical treatment (no further changes during the follow-up) were 19 % [95 % confidence interval (CI) 11-28] and 25 % (95 % CI 17-35), respectively, and the 1- and 3-year incidences of a final switch to surgery were 14 % (95 % CI 8-22) and 16 % (95 % CI 9-24), respectively. An initial tumor size of >7 cm was associated with a higher strategy modification risk (p = 0.004). Of the 102 patients initially observed, 29 experienced spontaneous regression over a median follow-up period of 32 months. All second-intent resections were macroscopically completed, with R0 resections achieved in 82 % of patients.
CONCLUSIONS: This study supports an initial nonsurgical approach to abdominal wall DTs ≤7 cm, followed by surgery based on tumor growth in select cases.

Entities:  

Mesh:

Year:  2013        PMID: 24052312     DOI: 10.1245/s10434-013-3197-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  54 in total

1.  Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.

Authors:  Daniel Robert Quast; Ralph Schneider; Emanuel Burdzik; Steffen Hoppe; Gabriela Möslein
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

2.  Sorafenib for Advanced and Refractory Desmoid Tumors.

Authors:  Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

3.  Radiotherapy in desmoid tumors : Treatment response, local control, and analysis of local failures.

Authors:  Kirsi Santti; Annette Beule; Laura Tuomikoski; Mikko Rönty; Anna-Stina Jääskeläinen; Kauko Saarilahti; Hanna Ihalainen; Maija Tarkkanen; Carl Blomqvist
Journal:  Strahlenther Onkol       Date:  2017-01-02       Impact factor: 3.621

4.  Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies.

Authors:  Andrew J Bishop; Jace P Landry; Christina L Roland; Ravin Ratan; Barry W Feig; Bryan S Moon; Maria A Zarzour; Wei-Lien Wang; Alexander J Lazar; Valerae O Lewis; Keila E Torres; B Ashleigh Guadagnolo
Journal:  Cancer       Date:  2020-04-28       Impact factor: 6.860

Review 5.  Locally Aggressive Connective Tissue Tumors.

Authors:  Mrinal M Gounder; David M Thomas; William D Tap
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

6.  Undervaluation of Radiotherapy for Gross Desmoid Tumors: The Need for Absolute Volume Assessment.

Authors:  Yeon Joo Kim; Si Yeol Song; Wanlim Kim; Jongseok Lee; Jin-Hee Ahn; Jeong Eun Kim; Hye Won Chung; Seong-Yun Jeong; Eun Kyung Choi
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

7.  MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

Authors:  Firouzeh Kamali; Wei-Lien Wang; B A Guadagnolo; Patricia S Fox; Valerae O Lewis; Alexander J Lazar; Anthony P Conley; Vinod Ravi; Mohammad Toliyat; Harshad S Ladha; Brian P Hobbs; Behrang Amini
Journal:  Br J Radiol       Date:  2015-11-18       Impact factor: 3.039

8.  Desmoid fibromatosis: MRI features of response to systemic therapy.

Authors:  Pooja J Sheth; Spencer Del Moral; Breelyn A Wilky; Jonathan C Trent; Jonathan Cohen; Andrew E Rosenberg; H Thomas Temple; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2016-08-09       Impact factor: 2.199

Review 9.  Fibromatosis of the breast: a 10-year multi-institutional experience and review of the literature.

Authors:  Michael R Boland; Timothy Nugent; Jack Nolan; Johnny O'Mahony; Sylvia O'Keeffe; Charles C Gillham; Aoife Maguire; James Geraghty; Damian McCartan; Denis Evoy; Ruth S Prichard; Enda W McDermott; Dhaffir Alazawi; Terence J Boyle; Elizabeth M Connolly
Journal:  Breast Cancer       Date:  2020-08-11       Impact factor: 4.239

Review 10.  The Role of Radiation Therapy for Symptomatic Desmoid Tumors.

Authors:  Wen Shen Looi; Daniel J Indelicato; Michael S Rutenberg
Journal:  Curr Treat Options Oncol       Date:  2021-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.